Mevalonate kinase deficiency (MKD): long-term follow-up of clinical and biological features in 40 patients by Florkin, B et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Pediatric Rheumatology
Open Access Poster presentation
Mevalonate kinase deficiency (MKD): long-term follow-up of clinical 
and biological features in 40 patients
B Florkin*1, L Cuisset2, C Acquaviva-Bourdain3, D Rabier4, B Neven1, 
P Quartier1 and AM Prieur1
Address: 1Necker Enfants Malades Hospital, Immuno-hemato-rheumatology Unit, Paris, France, 2Cochin Hospital Molecular Genetics, Paris, 
France, 3Debrousse Hospital, Lyon, France and 4Necker Enfants Malades Hospital, Biochemistry Department, Paris, France
* Corresponding author    
MKD causes hyper-IgD syndrome and mevalonic aci-
duria. Disease severity and clinical phenotype has not yet
been linked to specific mutations. In this study, we
intended to review clinical presentation and outcome of
pediatric and adult patients.
40 patients were identified through MVK mutation data-
base in one central reference laboratory and physicians'
networking.
Medical charts were reviewed (21/40) or questionnaires
were filled in by treating physician (19/40).
Follow-up ranged from 2 years to 60 years. First symp-
toms occurred before age 2 in 90% of patients. Main clin-
ical features were fever (100%), abdominal pain (92%),
diarrhea (88%), enlarged lymph nodes (88%), skin rash
(86%), arthralgias (85%), arthritis (43%), growth delay
(33%), CNS white matter involvement (7,5%) and mac-
rophage activation syndrome (5%). We recorded 3 dis-
ease-related deaths. IgD level ranged from normal (<100
IU/ml) to 2614 IU/ml and were persistently normal in 6
patients. IgA level was above upper limit in all but 2
patients. Mevalonate kinase activity was deeply impaired
(0,7–7% of normal controls). The most prevalent muta-
tion was V377I. In 3 independent kindreds, only one
mutated allele was found in the coding sequence of the
gene. Most patients received NSAIDs, steroids and colch-
icin. Etanercept and anakinra at high doses showed some
efficacy. Some patients were refractory to all treatments.
One patient succesfully received allogenic stem cell trans-
plantation.
MKD is a challenging condition, with a wide array of
severity, potentially severe complications and a high bur-
den on quality of life.
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